The filing contains early-stage pipeline news with no clinical data or financial disclosures. The upcoming Q2 2026 earnings call on August 20 is the next catalyst to watch for revenue/cash position updates. Until then, the announcement lacks material near-term catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 17 $3.13entry
- T+1 · 3mo ago +0.64%α +1.31% · $3.15
- T+5 · 3mo ago +8.63%α +9.82% · $3.40
- T+20 · 2mo ago −2.88%α −0.90% · $3.04
- T+60 · 7d ago −8.63%α −5.68% · $2.86
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion announced a pipeline refocusing, adding a new glioblastoma vaccine program (EVX-05) in collaboration with Duke University while discontinuing the EVX-03 program. The company reiterated its cash runway into H2 2027 and stated EVX-05 costs are within existing budgets, but no financial figures or clinical data were provided. This is a preclinical-stage pipeline update with no near-term revenue or catalyst data.
Key Facts
- New glioblastoma vaccine program EVX-05 announced, off-the-shelf, targeting ERV-derived antigens, in collaboration with Duke University.
- Evaxion maintains cash runway into the second half of 2027; EVX-05 costs are within existing budgets.
- EVX-03 program discontinued.
- No financial figures, clinical data, or guidance were provided in this filing.
- Q2 2026 earnings call/webcast scheduled for August 20, 2026.
Financial Impact
No financial impact data disclosed in the filing. Cash runway into H2 2027 reiterated; pipeline refocus with no incremental cost.
Risk Factors
- No clinical data for EVX-05; program is at preclinical optimization stage.
- Discontinuation of EVX-03 removes a pipeline asset.
- Pre-revenue clinical-stage biotech with high cash burn; cash runway into H2 2027 provides limited visibility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005577 |
| Document: f6k_081726.htm | 0001171843-26-005577 |
| Document: 0001171843-26-005577-index-headers.html | 0001171843-26-005577 |
| Document: 0001171843-26-005577-index.html | 0001171843-26-005577 |
| Document: 0001171843-26-005577.txt | 0001171843-26-005577 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers